

CURRICULUM VITAE

Name: Professor Richard Russell	
Present appointment:	
Consultant Paediatric Gastroenterologist, Department of Paediatric Gastroenterology	
Address:	
Department of Paediatric Gastroenterology Clinical Staff Offices, 2nd Floor, Royal Hospital for Children and Young People 50 Little France Crescent, Edinburgh EH16 4TJ	
Qualifications:	
MB ChB	1993, PhD 2008
MRCP (UK)	1998, MRCPCH 1998
CCT	2007
Professional registration:	
GMC registration number:	4043108 (revalidation next due 3/25)
Other appointments:	
<ul style="list-style-type: none"> • Lead for GI service in Southeast Scotland • Chair of the ESPGHAN Porto Group 	
Research experience:	
I have been PI/CI on more than 10 clinical research trials in Paediatric IBD involved extensively from inception, through recruitment to closure and publication including CI on multicentre CTIMP in PIBD.	
Research training:	
I have up to date GCP certification (last renewed January 2023)	
Grants: In collaboration	
Totals: Ever 26 Current 2; Total Money > £5,500,000 Current > £1,000,000	
Relevant publications:	
Selected Publications (Total >180 publications, >18,000 citations, h-Index 55):	
1. Gaya DR, Russell RK , Nimmo ER, Satsangi J. New genes in inflammatory bowel disease: lessons for complex diseases? The Lancet 2006; 367(9518):1271-84.	
2. Russell RK , et al. Analysis of the influence of OCTN1/2 variants within the IBD5 locus on disease susceptibility and growth indices in early onset inflammatory bowel disease. Gut 2006; 55(8):1114-1123.	
3. Van Limbergen J, Russell RK* , ... Satsangi J, Wilson DC. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology 2008; 135(4):1114-1122. (*joint first author)	
4. Imielinski M, Baldassano RN, Griffiths A, Russell RK* , Wilson DC, Hakonarson H. Common variants at five new loci associated with early-onset inflammatory bowel disease. Nature Genetics 2009; 41(12):1335-40. (*joint first author)	
5. Levine A, Griffiths A, Markowitz J, Wilson DC, Turner D, Russell RK , Fell J, Ruemmele FM, Walters T, Sherlock M, Dubinsky M, Hyams JS. Pediatric Modification of the Montreal Classification for Inflammatory Bowel Disease - the Paris Classification. Inflammatory Bowel disease 2011; 17(6)1314-1321.	
6. Jostins L, Ripke S, Weersma R, Duerr RH, McGovern DP, Hui K, Lee J, Schumm P, Sharma Y, Anderson CA..... Russell RK Hakonarson H, Brandt SR, Radford-Smith G, Mathew CG, Schadt E, Daly MJ, Franke A, Parkes M, Vermeire S, Barrett JC, Cho JH. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012; 491 (7422):119-124.	
7. Heap, GA, Weedon MN, Bewshea CM, Singh A, So K, Dubois P, Vivian JP, Andrews, JM..... Russell RK Ahmad T. HLA DQA1-DRB1 variants predispose to pancreatitis induced by the thiopurine immunosuppressants. Nature Genetics 2014; 46(10):1131-4.	
9. Li YR, Li J, Zhao SD, Bradfield JP, ... Russell RK , Wilson D, ... Hongzhe Li, Keating BJ. Meta-analysis of shared genetic architecture across ten pediatric autoimmune diseases.	

Nature Medicine 2015;21(9):1018-27.

10. Turner D, Hussey S, Stanton M, Pakarinen M, de Ridder L, Katsanos K, Croft N, Navas V, Wilson DC, Lawrence S, **Russell RK**. Management of paediatric ulcerative colitis, Part 1: ambulatory care; an evidence-based consensus guideline from ECCO and the Paediatric IBD Porto group of ESPGHAN. JPGN 2018;67(2):257-291.
11. Svolos V, Hansen R, **Russell RK**, Gerasimidis K. Treatment of Active Crohn's Disease With an Ordinary Food-based Diet That Replicates Exclusive Enteral Nutrition. Gastroenterology 2019;156(5):1354-1367.
12. Kennedy NA, **Russell RK**, ... Ahmad T. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. Lancet Gastroenterology Hepatology 2019;4(5):341-353.
13. Walker GJ, Harrison JW, **Russell RK**,, Xavier R, Ward R, Weedon MN, Goodhand JR, Kennedy NA, Ahmad T; IBD Pharmacogenetics Study Group. Association of Genetic Variants in NUDT15 With Thiopurine-Induced Myelosuppression in Patients with Inflammatory Bowel Disease. JAMA 2019 ;321(8):773-785.
14. Turner D, Griffiths A, Wilson DC, Mould DR, Baldassano R, **Russell RK**, Dubinsky MC, Heyman MB, de Ridder L, Hyams JS, Martín-de-Carpi J, Conklin LS, Bousvaros A, Ruemmele FM. Designing clinical trials in paediatric inflammatory bowel diseases: a PIBDnet commentary. Gut 2020; 69(1):32-41.
15. Cozijnsen MA, Ben Shoham A, Kang B, Choe BH, Choe YH, Jongsma MM, **Russell RK**, ..., Griffiths A, Turner D. Development and Validation of the Mucosal Inflammation Non-invasive Index For Pediatric Crohn's Disease. Clinical Gastroenterology and Hepatology 2020;18(1):133-140.
16. Zafeiropoulou K, Nichols B,, **Russell RK**, McGrogan P, Edwards CA, Ijaz UZ, Gerasimidis K. Alterations in Intestinal Microbiota of Children With Celiac Disease at Time of Diagnosis and on a Gluten-Free Diet. Gastroenterology 2020;159(6):2039-2051.
17. Meyer EO, ... **Russell RK**, L, Griffiths AM, Turner D. Predicting Outcomes in Pediatric Ulcerative Colitis for Management Optimization: Systematic Review and Consensus Statements from PIBD-Ahead Program. Gastroenterology 2021;160(1):378-402.
18. Ricciuto A, ... **Russell RK**, Veres G, Walters T, Wilson D, Kaiser T, de Ridder L, Turner D, Griffiths AM. Predicting Outcomes to Optimize Disease Management in Pediatric Crohn's Disease: Consensus Statements by the PIBD Ahead Steering Committee. Gastroenterology 2021;160(1):403-436
19. Kennedy NA, Goodhand JR, ..., **Russell RK**, ... Powell N, Ahmad T. Anti-SARS-CoV2 antibody responses are impaired in patients with inflammatory bowel disease treated with infliximab. Gut 2021;70(5):865-875.
20. Focht G, ... **Russell RK**, Gavish M, Griffiths AM, Turner D. Development, validation and evaluation of the Pediatric Inflammatory Crohn's Magnetic Resonance Enterography Index (PICMI) from the ImageKids study. Gastroenterology 2022;163(5):1306-1320.
21. Burgess CJ, Jackson R, Chalmers I, **Russell RK**, Hansen R, Henderson P, Wilson DC. The inexorable increase of biological exposure in paediatric Inflammatory Bowel Disease: a Scottish, population-based, longitudinal study. Alimentary Pharmacology & Therapeutics 2022;56(10):1453-1459.
22. Atia O, **Russell RK**. Turner D. Outcomes, dosing, and predictors of vedolizumab treatment in children: results from the prospective, multicenter VEDOKIDS study. The Lancet Gastroenterology & Hepatology 2023;8(1):31-42.

Signature:

Richard Russell

Date:

30.5.23